AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 262 min read$CORT

Corcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) reported positive Phase 2 BELLA trial results for Lifyoril (relacorilant) in platinum-resistant ovarian cancer. The combination therapy achieved a median PFS of 7.2 months and ORR of 59%. The stock closed at $85.86 on Friday, up 2.49% in pre-market trading.

Original reporting
rttnews.com
Published Oct 26, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CORT
Bullish
high confidence
Mentioned
$CORT
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CORTBullishMed
01

Why it matters

The disclosed median PFS of 7.2 months and ORR of 59% represent a meaningful efficacy signal, likely prompting analyst upgrades and short‑term buying interest.

02

Market read

First‑time release of Phase 2 data for a niche oncology drug; could move CORT and related biotech stocks.

03

What to watch

Potential competition from other GR antagonists and the need for larger Phase 3 data.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Corcept Therapeutics (CORT) is a specialty pharma company developing selective glucocorticoid receptor antagonists. The BELLA trial evaluates relacorilant combined with chemotherapy and bevacizumab in a hard‑to‑treat ovarian cancer population.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

Corcept Therapeutics reported positive Phase 2 BELLA trial results for relacorilant in platinum‑resistant ovarian cancer, a first disclosure of new clinical data.

Expected impact

likely upward pressure as market prices in the encouraging efficacy and survival signals.

Evidence & confidence

Phase 2 data are material for a biotech; the results exceed typical expectations and were not previously public.

Market effects

Sector

strengthens the oncology/GR‑antagonist niche and may boost peer biotech valuations.

Regional

U.S. biotech sector may see modest gains in early trading.

Global

Limited to investors focused on cancer therapeutics and specialty pharma.

Counterpoint

What could challenge this read

If later-stage data fail to confirm efficacy, the current rally could reverse sharply.

Key entities

  • company
    Corcept Therapeutics

    US‑listed biotech developing relacorilant.

  • drug
    relacorilant (Lifyoril)

    Selective glucocorticoid receptor antagonist under trial.

Read at source← All news

StoryCorcept Therapeutics reports positive Phase 2 BELLA trial results for Lifyorli in platinum‑resistant ovarian cancer

Also covered by

1 outlet

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min
SEP 19
$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min